全文获取类型
收费全文 | 10332篇 |
免费 | 463篇 |
国内免费 | 136篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 162篇 |
妇产科学 | 69篇 |
基础医学 | 1112篇 |
口腔科学 | 278篇 |
临床医学 | 633篇 |
内科学 | 2800篇 |
皮肤病学 | 144篇 |
神经病学 | 716篇 |
特种医学 | 433篇 |
外科学 | 2218篇 |
综合类 | 35篇 |
预防医学 | 215篇 |
眼科学 | 130篇 |
药学 | 579篇 |
中国医学 | 17篇 |
肿瘤学 | 1313篇 |
出版年
2023年 | 81篇 |
2022年 | 45篇 |
2021年 | 258篇 |
2020年 | 167篇 |
2019年 | 183篇 |
2018年 | 237篇 |
2017年 | 191篇 |
2016年 | 247篇 |
2015年 | 257篇 |
2014年 | 363篇 |
2013年 | 447篇 |
2012年 | 690篇 |
2011年 | 744篇 |
2010年 | 406篇 |
2009年 | 358篇 |
2008年 | 640篇 |
2007年 | 664篇 |
2006年 | 669篇 |
2005年 | 720篇 |
2004年 | 709篇 |
2003年 | 645篇 |
2002年 | 638篇 |
2001年 | 129篇 |
2000年 | 104篇 |
1999年 | 146篇 |
1998年 | 158篇 |
1997年 | 116篇 |
1996年 | 114篇 |
1995年 | 86篇 |
1994年 | 81篇 |
1993年 | 77篇 |
1992年 | 71篇 |
1991年 | 71篇 |
1990年 | 50篇 |
1989年 | 57篇 |
1988年 | 37篇 |
1987年 | 26篇 |
1986年 | 34篇 |
1985年 | 24篇 |
1984年 | 24篇 |
1983年 | 21篇 |
1982年 | 12篇 |
1981年 | 17篇 |
1980年 | 11篇 |
1979年 | 15篇 |
1978年 | 12篇 |
1977年 | 9篇 |
1975年 | 11篇 |
1972年 | 8篇 |
1969年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Nicolas Zhou Matthew Bott Bernard J. Park Eric Vallières Candice L. Wilshire Kazuhiro Yasufuku Jonathan D. Spicer David R. Jones Boris Sepesi 《The Journal of thoracic and cardiovascular surgery》2021,161(3):760-771.e2
BackgroundAdjuvant chemotherapy, postoperative radiation (PORT), and prophylactic cranial irradiation (PCI) have been individually examined in limited-stage small cell lung cancer (SCLC). There is a paucity of data on the effectiveness of each adjuvant treatment modality when used in combination after surgical resection of SCLC.MethodsData were collected from 5 cancer centers on all patients with limited-stage SCLC who underwent surgical resection between 1986 and 2019. Univariate and multivariable models were conducted to identify predictors of long-term outcomes, focusing on freedom from recurrence and survival benefit of adjuvant chemotherapy, PORT, and PCI.ResultsA total of 164 patients were analyzed. Multivariable Cox regression analysis did not identify any adjuvant therapies to significantly influence recurrence in this cohort. Specifically, PORT was not associated with a significant influence on locoregional recurrence and PCI was not significantly associated with intracranial outcomes. Adjuvant chemotherapy improved survival in all stage I through III disease (hazard ratio, 0.49; 95% confidence interval, 0.29-0.81; P = .005) and even in pathologically node negative patients (hazard ratio, 0.49; 95% confidence interval, 0.27-0.91; P = .024). Although PCI was found to improve survival in univariate analysis, it was not significant in a multivariable model. PORT was not found to affect survival on either univariate or multivariable analysis.ConclusionsThis is among the largest multi-institutional studies on surgically resected limited-stage SCLC. Our results highlight survival benefit of adjuvant chemotherapy, but did not identify a statistically significant influence from mediastinal PORT or PCI in our cohort. Larger prospective studies are needed to determine the benefit of PORT or PCI in a surgically resected limited-stage SCLC population. 相似文献
2.
Tetsuji Terazawa Takeshi Kato Masahiro Goto Katsuya Ohta Shingo Noura Hironaga Satake Yoshinori Kagawa Hisato Kawakami Hiroko Hasegawa Kazuhiro Yanagihara Tatsushi Shingai Ken Nakata Masahito Kotaka Masayuki Hiraki Ken Konishi Shiro Nakae Daisuke Sakai Yukinori Kurokawa Toshio Shimokawa Taroh Satoh 《The oncologist》2021,26(1):17-e47
Lessons Learned
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.
3.
4.
Kenji Takagishi Tetsuya Matsuura Takashi Masatomi Etsuo Chosa Tsuyoshi Tajika Tetsu Iwama Mikihiko Watanabe Toshiro Otani Katsunori Inagaki Hiroyasu Ikegami Mitsuhiro Aoki Toru Okuwaki Yasushi Kameyama Maeda Akira Koji Kaneoka Masaaki Sakamoto Moroe Beppu 《Journal of orthopaedic science》2019,24(4):708-714
BackgroundDespite proposals and guidelines to prevent baseball injuries in young players by societies and organizations, many shoulder and elbow injuries continue to occur among junior high school baseball players. In order to investigate the training conditions of junior high school baseball players and the risk factors for shoulder and elbow pain in the players, we conducted a questionnaire survey among junior high school baseball players throughout the country.MethodsThe questionnaire survey was conducted among junior high school baseball players in September 2016.ResultsA total of 11,134 junior high school baseball players belonging to 495 teams responded to the survey. Among these, 4004 players trained every day of the week and 1151 players played baseball games every month with no off-season. Among 9752 players who did not have shoulder and/or elbow pain in the spring and summer of 2015, 19.2% of players experienced elbow pain over the course of one year, 13.6% of players experienced shoulder pain, and 28.0% complained of shoulder and/or elbow pain. The frequency of elbow pain was more than that of shoulder pain. At risk for shoulder pain were pitchers and catchers and second-year students, while risk factors for elbow pain were playing pitcher and catcher positions, pitching or throwing ≥300 balls per week, playing ≥10 games on average per month and being left-handed.ConclusionRisk factors for shoulder pain were different from those for elbow pain. To prevent elbow pain, coaches should pay attention to pitchers and catchers and left-handed players and not allow players to pitch or throw ≥300 full-power balls per week or participate in ≥10 games per month. They should also pay attention to pitchers and catchers and second-year students to prevent shoulder pain. It is important for coaches to train multiple pitchers and catchers. 相似文献
5.
6.
7.
8.
Tada Kazuhiro Iwashita Yukio Shiraiwa Ken Uchida Hiroki Oshima Yusuke Sato Yuhki Nakanuma Hiroaki Hirashita Teijiro Masuda Takashi Endo Yuichi Takeuchi Yu Ohta Masayuki Itoh Hiroki Inomata Masafumi 《Cancer chemotherapy and pharmacology》2020,85(2):345-352
Cancer Chemotherapy and Pharmacology - Chemotherapy after hepatectomy for colorectal liver metastasis has not been established, due to the toxic side effects, which are likely related to impaired... 相似文献
9.
Yoshinori Yanai Takeo Kosaka Kohei Nakamura Eriko Aimono Kazuhiro Matsumoto Shinya Morita Shuji Mikami Hiroshi Nishihara Mototsugu Oya 《Cancer science》2020,111(12):4652
Cyclin‐dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb‐B2 receptor tyrosine kinase 2 (ERBB2). In this report, CDK12 and ERBB2 coamplification was detected by targeted next‐generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor‐2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients. 相似文献